Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, T-Cell, Peripheral 6Hematologic Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Parathyroid Neoplasms 2Otorhinolaryngologic Neoplasms 2Osteosarcoma 2Neoplasms 2Multiple Myeloma 2Mixed Tumor, Mesodermal 2Mesothelioma, Cystic 2Mesothelioma 2Lymphoma, T-Cell 2Lymphoma 2Liposarcoma 2Leiomyosarcoma 2Kidney Neoplasms 2Hemangiosarcoma 2Head and Neck Neoplasms 2Fibrosarcoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Chondrosarcoma 2Carcinoma, Small Cell 2Breast Neoplasms 2Adenosarcoma 2

Interventions

Lenalidomide 2Dexamethasone 2Bortezomib 2darinaparsin 1carfilzomib 1belinostat 1SCIO-469 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bone Marrow Neoplasms × belinostat × Clear all
NCT00431340 2015-07-08

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Valerio Therapeutics

Phase 2 Terminated
4 enrolled
Plasma cell

Multiple Myeloma, Bone Marrow Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡